Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
42205674
Type of treatment:
Allogeneic
Diseases:
Myelodysplastic (MDS) or MDS/MPN
Short title:
Primary objective:
To evaluate the impact of additional adverse cytogenetic abnormalities on relapse-free survival after allo-SCT in MDS with very poor risk cytogenetics.
Key inclusion criteria:
MDS
CR1, CR2 and beyond
Age >= 18
MDS with more than 3 cytogenetic abnormalities at diagnosis
First allogeneic SCT
Allogeneic SCT from matched family or matched unrelated donor between 2000 and 2016
CR1, CR2 and beyond
Age >= 18
MDS with more than 3 cytogenetic abnormalities at diagnosis
First allogeneic SCT
Allogeneic SCT from matched family or matched unrelated donor between 2000 and 2016
Country:
All EBMT member countries
Principal investigator:
Xavier Poiré
EBMT Study coordinator:
Linda Koster
Study coordinator email:
cmwp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results